These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 1311436)

  • 41. Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine.
    Bianchi G; Vitali G; Caraceni A; Ravaglia S; Capri G; Cundari S; Zanna C; Gianni L
    Eur J Cancer; 2005 Aug; 41(12):1746-50. PubMed ID: 16039110
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High-dose cisplatin-related peripheral neuropathy.
    Ostchega Y; Donohue M; Fox N
    Cancer Nurs; 1988 Feb; 11(1):23-32. PubMed ID: 2834044
    [No Abstract]   [Full Text] [Related]  

  • 43. High-dose cisplatin and vinblastine plus amifostine for metastatic non-small cell lung cancer.
    Schiller JH
    Semin Oncol; 1996 Aug; 23(4 Suppl 8):78-82. PubMed ID: 8783672
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Semax in the treatment of glaucomatous optic neuropathy in patients with normalized ophthalmic tone].
    Kurysheva NI; Shpak AA; Ioĭleva EE; Galanter LI; Nagornova ND; Shubina NIu; Shlyshalova NN
    Vestn Oftalmol; 2001; 117(4):5-8. PubMed ID: 11569188
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The ACTH (4-9) analog ORG 2766 in panic disorder: a preliminary study.
    den Boer JA; Westenberg HG; Mastenbroek B; van Ree JM
    Psychopharmacol Bull; 1989; 25(2):204-8. PubMed ID: 2557650
    [No Abstract]   [Full Text] [Related]  

  • 46. Amifostine in reducing cisplatin toxicity.
    Markman M
    Semin Oncol; 1998 Oct; 25(5):522-4. PubMed ID: 9783591
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cisplatin-associated neurotoxicity: can it be prevented?
    Alberts DS; Noel JK
    Anticancer Drugs; 1995 Jun; 6(3):369-83. PubMed ID: 7670134
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High-dose (200 mg/m2) cisplatin-induced neurotoxicity in primary advanced ovarian cancer patients.
    Panici PB; Greggi S; Scambia G; Di Roberto P; Iacobelli S; Mancuso S
    Cancer Treat Rep; 1987 Jun; 71(6):669-70. PubMed ID: 3034424
    [No Abstract]   [Full Text] [Related]  

  • 49. Deficits in social behavior in autism and their modification by a synthetic adrenocorticotrophic hormone (4-9) analog.
    Buitelaar JK; van Engeland H; de Kogel CH; de Vries H; van Hooff JA; van Ree JM
    Experientia; 1992 Apr; 48(4):391-4. PubMed ID: 1316288
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Glutathione and detoxification.
    Tedeschi M; Bohm S; Di Re F; Oriana S; Spatti GB; Tognella S; Zunino F
    Cancer Treat Rev; 1990 Sep; 17(2-3):203-8. PubMed ID: 2272034
    [No Abstract]   [Full Text] [Related]  

  • 51. Study of cisplatin-vinblastine plus amifostine in patients with locally advanced or metastatic non-small cell lung cancer.
    Thongprasert S; Chewaskulyong B
    J Med Assoc Thai; 2004 Oct; 87(10):1162-7. PubMed ID: 15560691
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Relationship between the therapeutic effect of the peptide preparation semax and the severity of brain ischemia].
    Khugaeva VK; Aleksandrin VV
    Biull Eksp Biol Med; 1997 Jul; 124(7):39-42. PubMed ID: 9303728
    [No Abstract]   [Full Text] [Related]  

  • 53. [Study of the analgesic effect of the semax preparation].
    Koroleva MV; Meĭzerov EE; Nezavibat'ko VN; Kamenskiĭ AA; Dubynin VA; Iakovlev IuB
    Biull Eksp Biol Med; 1996 Nov; 122(11):527-9. PubMed ID: 8998343
    [No Abstract]   [Full Text] [Related]  

  • 54. [Study of the efficacy of semax in global cerebral ischemia in vivo].
    Iakovleva EV; Kuzenkov VS; Fedorov VN; Skvortsova VI; Koshelev VB; Gusev EI; Ashmarin IP
    Biull Eksp Biol Med; 1999 Aug; 127(8):172-4. PubMed ID: 11188738
    [No Abstract]   [Full Text] [Related]  

  • 55. Acute neurological disorders following intraperitoneal administration of cisplatin.
    Simkens GA; Hanse MC; de Hingh IH
    Int J Gynaecol Obstet; 2013 Mar; 120(3):291. PubMed ID: 23245673
    [No Abstract]   [Full Text] [Related]  

  • 56. ACTH analogue application to oncostatic chemotherapy. A double blind approach.
    Piazza E; Cattaneo MT; Colombo F; Libretti A
    Ric Clin Lab; 1984; 14(2):257-9. PubMed ID: 6091252
    [No Abstract]   [Full Text] [Related]  

  • 57. High-dose cisplatin therapy for cancer of the ovary: neurotoxicity.
    Bagley CM; Rudolph RH; Rivkin SE; Yon JL
    Ann Intern Med; 1985 May; 102(5):719. PubMed ID: 4039114
    [No Abstract]   [Full Text] [Related]  

  • 58. The role of glutathione in combination with cisplatin in the treatment of ovarian cancer.
    Tedeschi M; De Cesare A; Oriana S; Perego P; Silva A; Venturino P; Zunino F
    Cancer Treat Rev; 1991 Dec; 18(4):253-9. PubMed ID: 1842576
    [No Abstract]   [Full Text] [Related]  

  • 59. Therapeutic potential for melanocortins in peripheral nerve disease.
    Gispen WH
    Trends Pharmacol Sci; 1990 Jun; 11(6):221-2. PubMed ID: 2166368
    [No Abstract]   [Full Text] [Related]  

  • 60. Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721.
    Mollman JE; Glover DJ; Hogan WM; Furman RE
    Cancer; 1988 Jun; 61(11):2192-5. PubMed ID: 2835140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.